Unknown PHASE3 INTERVENTIONAL 2-arm NCT01980849

Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (LCAN)

Phase Ⅲ Study of Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer by Nadroparin

Sponsor: Shengqing Li

Interventions Nadroparin, long term Nadroparin: short-term

Updated 7 times since 2017 Last updated: Nov 20, 2013 Started: Nov 30, 2013 Primary completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Lung Cancer and is currently ongoing. Shengqing Li leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Nov 2020 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 2 earlier versions

Jun 2018 — Nov 2020 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shengqing Li

Data source: Air Force Military Medical University, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baoji, China , Baotou, China , Chengdu, China , Chongqing, China , Hohhot, China , Taiyuan, China , Xi'an, China , Xinxiang, China , Yan’an, China , Yinchuan, China and 2 more locations